Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases

This publication has 120 references indexed in Scilit:

• Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
  Investigational New Drugs, 2023
• Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
  Investigational New Drugs, 2021
• Structure–activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety
  Molecular Diversity, 2020
• Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
  Cancer Chemotherapy and Pharmacology, 2018
• Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism
  Cardiovascular Toxicology, 2017
• The MAP Kinase Signaling Cascades: A System of Hundreds of Components Regulates a Diverse Array of Physiological Functions
  2010
• B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma
  Current Oncology Reports, 2010
• Dual-specificity MAP kinase phosphatases (MKPs) and cancer
  Cancer and Metastasis Reviews, 2008
• Activation of Raf-1 in Human Pancreatic Adenocarcinoma
  Journal of Surgical Research, 1997
• ERK phosphorylation potentiates Elk‐1‐mediated ternary complex formation and transactivation.
  The EMBO Journal, 1995